ClinicalTrials.gg
RecruitingNCT06302582Updated Mar 12, 2024

Platelet Rich Plasma Combined With Human Umbilical Cord Mesenchymal Stem Cells for Stage 3 and 4 Stress Injury

A Phase 1/2 interventional study of Platelet-rich plasma (PRP) combined with human umbilical cord mesenchymal stem cells (huMSCs) and Control group in Pressure Injuries - Stage 3 and Pressure Injuries - Stage 4, sponsored by Liaocheng People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-03-12.

Sponsored by Liaocheng People's Hospital · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 1 year 11 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Pressure Ulcer with a site in China — 7 open to participants now, 8 under way, none of them phase 3. Pressure Ulcer · China.

Started
2024
with 2 others
Phase 1/2
Only one
of the 14
Registered
7th of 14
by date
Lead sponsor
1 of 14
Liaocheng People's Hospital

Among the 14 studies in Pressure Ulcer with a site in China, this one is one of 3 that started in 2024, is the only one in phase 1/2, and was the 7th registered.

Pressure Ulcer

548 studies on the registry are indexed under Pressure Ulcer; 127 are open to participants now.

Browse Pressure Ulcer studies →

Open to participants now

7 of the 14 studies in Pressure Ulcer with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 61 Pressure Ulcer studies recruiting now, 45 (74%) set no upper age limit and 6 (10%) stop at 75 or younger; 10 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Pressure Ulcer with a site in China, or all of them as a file.
02

Study summary

This study is an open-label, single-center trial which aim to evaluate of efficacy and safety of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) combined with platelet-rich plasma (PRP) in stage 3 and 4 stress injury.

Read the detailed description

The 2019 edition of the International Guidelines for Clinical Prevention and Treatment of Stress Injury states that stress injury, as a globally prevalent health issue, significantly reduces the quality of life for patients and their families, increases economic burden, and leads to significant expenditure on medical resources. In recent years, the incidence and mortality rate of pressure injuries in hospitalized patients have been increasing year by year. Therefore, there is an urgent need to find a more effective treatment method for pressure injuries in clinical practice. Human umbilical cord mesenchymal stem cells (huMSCs) have immunomodulatory and anti-inflammatory effects. Platelet rich plasma (PRP) can also secrete various nutritional factors, which can effectively promote wound healing. Therefore, the combination of the two may be a more effective treatment method for pressure injuries. At present, there are few reports on the combination of PRP and huMSCs for the treatment of pressure injury. In this study, the investigators aim to evaluate the effectiveness and safety of PRP combined with huMSCs for stage 3 and 4 pressure injuries, In order to promote their clinical application.

03

Conditions studied

  • Pressure Injuries - Stage 3
  • Pressure Injuries - Stage 4

Browse trials for

Keywords

  • Mesenchymal stem cells
  • Platelet rich plasma
  • Pressure Injuries
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-80 years old, regardless of gender;
  • Patients with stage 3 and stage 4 pressure injuries (According to National Pressure Ulcer Advisory Panel (NPUAP)/European Pressure Ulcer Advisory Panel (EPUAP) classification system for pressure ulcers);
  • There were no complications affecting the wound healing;
  • After through debridement for the first time, the wound volume meets the requirement of "10-100cm3"; count before treatment 100\~300×109/L;
  • The patient voluntarily participates and signs an form.

Exclusion criteria

Exclusion Criteria:

  • Individuals with coagulation dysfunction or hemorrhagic diseases;
  • People with skin diseases, diabetes and immune diseases;
  • Individuals with mental or psychological disorders;
  • Individuals with allergies to multiple drugs;
  • Pregnant or lactating women;
  • Those who need to take medication that affects and coagulation function for a long time or in the near future, but have not stopped taking medication within the past week.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Platelet-rich plasma (PRP) combined with human umbilical cord mesenchymal stem cells (huMSCs)

    Inject 3ml PRP+huMSCs (5 × 106) into the edge and bottom of the wound, with 0.5 ml at each point and a distance of approximately 1-3 cm between each point. Then, apply autologous PRP gel (PRP+thrombin mixture, 2ml) evenly on the wound, with a thickness of about 2mm.

    Biological: Platelet-rich plasma (PRP) combined with human umbilical cord mesenchymal stem cells (huMSCs)

  • Other
    Control group

    Standard therapy

    Other: Control group

Interventions

  • BiologicalPlatelet-rich plasma (PRP) combined with human umbilical cord mesenchymal stem cells (huMSCs)

    Drug pages: Platelet rich plasmaStudies of Platelet rich plasmaPlatelet rich plasma pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · SolizmestrocelStudies of SolizmestrocelSolizmestrocel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Inject 3mL PRP+huMSCs (5 × 106) into the edge and bottom of the wound, with 0.5 ml at each point and a distance of approximately 1-3 cm between each point. Then, apply autologous PRP gel (PRP+thrombin mixture, 2ml) evenly on the wound, with a thickness of about 2mm

  • OtherControl group

    Standard therapy for patients with stage 3 and 4 stress injury

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Pressure Ulcer Scale for Healing (PUSH)

    The scale includes three dimensions: wound area, exudate volume, and tissue type. The total score of the three dimensions was indicated the healing of pressure injury and ranged from 0 to 17 points, with 0 points indicating wound healing. The PUSH score decreased, indicating improvement. The total score increased, indicating deterioration. Multiple pressure injuries in the same patient were evaluated separately.

    Time frame: Baseline,1,2,4 and 6 weeks

  2. Change from baseline in Determination of growth factor content

    Serum epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF) were detected during treatment.

    Time frame: Baseline,1, 2 and 3 weeks

Secondary outcomes

  1. Wound healing time

    The wound healing standard is wound closure and epithelial tissue coverage, and the wound healing time refers to the time from the date of direct treatment to wound healing for the patient. The wound healing time was recorded through dressing change in outpatient department or phone call follow-up.

    Time frame: up to 4 months

  2. Positive rate of bacterial culture

    The patient's wound secretions were collected for bacterial culture on the day of stem cell treatment and 2 weeks after treatment.

    Time frame: Baseline and 2 weeks

Other outcomes

  1. Safety evaluation

    Any adverse events that occur during the treatment process must be recorded in detail. The record of adverse events should include a description of the adverse event and all related symptoms, the time of occurrence, severity, duration, measures taken, and the final outcome and outcome, as well as an evaluation of the possible correlation between the adverse event and treatment.

    Time frame: up to 1 week

07

Study locations

1 of 1 sites recruiting
  • Central laboratory
    Liaocheng, Shandong 252000, China
    Recruiting
08

References and documents

Publications

  • Daneste H, Mohammadzadeh Boukani L, Ramezani N, Asadi F, Zaidan HK, Sadeghzade A, Ehsannia M, Azarashk A, Gholizadeh N. Combination therapy along with mesenchymal stem cells in wound healing; the state of the art. Adv Med Sci. 2023 Sep;68(2):441-449. doi: 10.1016/j.advms.2023.10.006. Epub 2023 Nov 2. PubMed 37924749 ↗
  • Qu S, Hu Z, Zhang Y, Wang P, Li S, Huang S, Dong Y, Xu H, Rong Y, Zhu W, Tang B, Zhu J. Clinical Studies on Platelet-Rich Plasma Therapy for Chronic Cutaneous Ulcers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Adv Wound Care (New Rochelle). 2022 Feb;11(2):56-69. doi: 10.1089/wound.2020.1186. Epub 2021 Jun 8. PubMed 33607926 ↗
  • Kunder V, Sharma KC, Rizvi Z, Soubelet R, Ducharme M. The Use of Platelet-Rich Plasma in the Treatment of Diabetic Foot Ulcers: A Scoping Review. Cureus. 2023 Aug 14;15(8):e43452. doi: 10.7759/cureus.43452. eCollection 2023 Aug. PubMed 37711926 ↗
  • Rainys D, Cepas A, Dambrauskaite K, Nedzelskiene I, Rimdeika R. Effectiveness of autologous platelet-rich plasma gel in the treatment of hard-to-heal leg ulcers: a randomised control trial. J Wound Care. 2019 Oct 2;28(10):658-667. doi: 10.12968/jowc.2019.28.10.658. PubMed 31600109 ↗
  • Wang Y, Luan S, Yuan Z, Wang S, Fan S, Ma C, Wu S. The Combined Use of Platelet-Rich Plasma Clot Releasate and Allogeneic Human Umbilical Cord Mesenchymal Stem Cells Rescue Glucocorticoid-Induced Osteonecrosis of the Femoral Head. Stem Cells Int. 2022 May 2;2022:7432665. doi: 10.1155/2022/7432665. eCollection 2022. PubMed 35547633 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2024; primary completion for Nov 2024, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2024
First posted
Mar 12, 2024
StartEst.
Feb 29, 2024
Primary completionEst.
Nov 25, 2024
CompletionEst.
Nov 25, 2024
Last update
Mar 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06302582
Lead sponsor
Liaocheng People's Hospital
Responsible party
Sponsor
First posted
Mar 12, 2024
Start date
Feb 29, 2024 (estimated)
Primary completion
Nov 25, 2024 (estimated)
Completion
Nov 25, 2024 (estimated)
Last update
Mar 12, 2024

Study contacts

Chunling Yang, bachelor
Contact
yangchunling01@126.com
13346256117 ext. 0635-8276115
1966-03-07
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Platelet rich plasma · Solizmestrocel

Start the discussion